Alligator Bioscience AB

ATORX

SE0000767188

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-29 am EDT			5-day change	1st Jan Change
0.925 ^SEK	0.00%		-6.94%	+34.25%

Apr. 26	Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	CI
Apr. 05	Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	CI

Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

April 05, 2024 at 02:00 am EDT

Alligator Bioscience AB (publ) at the annual general meeting to be held on 7 May 2024, Graham Dixon and Veronica Wallin are not proposed for re-election on the board.

Latest news about Alligator Bioscience AB

Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	Apr. 26	CI
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	Apr. 05	CI
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	Mar. 26	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	Mar. 07	CI
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024	Feb. 09
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan	Feb. 09	MT
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan	Feb. 09	MT
Alligator Bioscience to Trim Workforce Amid Restructuring Program	Feb. 08	MT
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 08	CI
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce	Feb. 08	CI
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation	Feb. 08	CI
Transcript : Alligator Bioscience AB - Special Call	Jan. 29
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	Jan. 29	CI
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody	Jan. 16	MT
Transcript : Alligator Bioscience AB - Analyst/Investor Day	Dec. 01
Certain Ordinary Shares of Alligator Bioscience AB are subject to a Lock-Up Agreement Ending on 9-NOV-2023.	Nov. 08	CI
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee	Nov. 06	CI
Transcript : Alligator Bioscience AB, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab	23-10-12	CI
Alligator Bioscience Obtains Orphan Status for Pancreatic Cancer Therapy in EU	23-08-21	MT
Alligator Bioscience Chief Operating Officer to Resign	23-08-17	MT
Alligator Bioscience AB Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October	23-08-17	CI
Alligator Bioscience Advances Research Partnership With Orion	23-07-31	MT
Alligator Bioscience AB Announces Technical Feasibility in the Second Program Under the Research Collaboration and License Agreement with Orion Corporation	23-07-31	CI

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alligator Bioscience AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.925 SEK

Average target price

2.3 SEK

Spread / Average Target

+148.65%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALLIGATOR BIOSCIENCE AB	+34.25%	63.95M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research